ArticleBlood advances2022

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.

Haiyan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.